Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo’s Revamp Signals Reversal From Previous CEO’s Diversification Strategy

This article was originally published in The Pink Sheet Daily

Executive Summary

Formerly of Valeant, new CEO Rajiv De Silva appears to be reworking Endo in the mold of his previous company, with plans to divest its early-stage pipeline and focus on growth through business development.

You may also be interested in...



Endo CEO Reveals Glimpse Of New Strategy: Highlights Generics Potential

During Endo’s first quarter sales and earnings call, new CEO Rajiv De Silva said his strategic review of the specialty pharma is still underway but offered investors some initial thoughts on his plans for the company.

Endo Aveed’s Safety Problems Weigh On Cmte., But Hope For Narrower Population Tips Scale For Some

FDA’s Reproductive Health Drugs and Risk Management advisory committees split on whether the safety of Endo’s injectable testosterone Aveed is safe for the proposed indication, with many on both sides seeing value in the drug for patients who “have to take testosterone.”

Endo’s Next Chapter Will Be Led By CEO De Silva

Former Valeant President De Silva joins Endo in the midst of a challenging year for the company, as two top-selling drugs face generic competition. De Silva will need to reenergize Endo and do so quickly if he is to maintain the early favor he appears to have won from investors.

Topics

Related Companies

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel